Excited that the dual PI3K/mTOR inhibitor gedatolisib was approved in breast cancer. Always nice to see positive clinical results for molecules my lab has studied. It is interesting as it causes large scale conformational changes in PI3K elifesciences.org/articles/64691, www.rcsb.org/structure/7JWE
Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors
The c-terminus of PI3K plays a key role in regulating kinase activity, with c-terminal disease-linked mutations leading to either activation or inhibition, which reveal a path to specific inhibitors.
elifesciences.org